about
What factors are important for deprescribing in Australian long-term care facilities? Perspectives of residents and health professionals.Analgesic Use and Pain in Robust, Pre-Frail and Frail Older Outpatients with Cancer.Polypharmacy cut-points in older people with cancer: how many medications are too many?Is my older cancer patient on too many medications?Are residents of aged care facilities willing to have their medications deprescribed?Prevalence and factors associated with polypharmacy in older people with cancer.Potentially inappropriate medication use in older people with cancer: prevalence and correlates.Statin use and pain in older people with cancer: a cross-sectional study.Factors associated with use of falls risk-increasing drugs among patients of a geriatric oncology outpatient clinic in Australia: a cross-sectional study.Older Adults' Awareness of Deprescribing: A Population-Based Survey.An Ecological Approach to Reducing Potentially Inappropriate Medication Use: Canadian Deprescribing Network.Opportunities for deprescribing statins in patients with poor cancer prognosis.Does a Consumer-Targeted Deprescribing Intervention Compromise Patient-Healthcare Provider Trust?Deprescribing conversations: a closer look at prescriber-patient communicationStrategies to promote public engagement around deprescribingImplementation of pharmacist-led medication reviews in general practicePatients' perspectives on the brave new word 'deprescribing'Leveraging policy to reduce chronic opioid use by educating and empowering community dwelling adults: a study protocol for the TAPERING randomized controlled trial
P50
Q36707350-81EEC857-AD2B-475D-8647-DC567430B984Q36942819-90D1560A-C97F-4DFC-843D-D343D24C8376Q38602643-05FD1915-0FBC-4842-90AE-FF92AD096A55Q39007096-1B8E365C-0844-40C2-9F75-4E18661F7BDAQ40926332-8586C389-56AF-4A76-BDE9-70C1CD716E91Q43982483-753D5754-7A6D-4C7F-836E-B34F34C6A1B2Q46890231-1A4AE68B-BE6F-48EE-8F61-79FF810219E2Q46975648-7C51AB81-A0F1-47D8-8C1A-34DF519CC10CQ48099014-7CC7209E-1469-4D30-BFB2-C9552B0D7CE8Q49663852-DB8DF611-4ECD-4519-8BA4-623D307B5131Q51150147-4B729B6A-8445-41CD-A946-406145E1B2D2Q54349401-BC6883A4-1005-4BE4-90E3-2B1CE59AE3B1Q55501037-240B102B-52A1-4358-8B6C-D8FFFA98CADFQ64320945-86227EA5-8AA8-4DA5-8900-7DD9D5C91341Q64322946-222A487B-4F4F-48CF-B806-9A02266CE086Q85369038-EA7B1E0C-E82F-46A5-BDC8-7D4C967CB28FQ86545120-5382A5E7-69CD-446F-BCA9-5C2536651B01Q91750884-9D148488-925C-4701-9BE6-AD72A89327C6
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Justin P Turner
@ast
Justin P Turner
@en
Justin P Turner
@es
Justin P Turner
@nl
type
label
Justin P Turner
@ast
Justin P Turner
@en
Justin P Turner
@es
Justin P Turner
@nl
prefLabel
Justin P Turner
@ast
Justin P Turner
@en
Justin P Turner
@es
Justin P Turner
@nl
P106
P1153
55442884900
P31
P496
0000-0003-0613-108X